IHC - Microsatellite Instability for Colorectal Carcinoma PMS-2

The IHC – Microsatellite Instability (PMS2) test for Colorectal Carcinoma is a specialized immunohistochemistry (IHC) diagnostic test used to detect PMS2 protein expression in colorectal cancer tissue samples. PMS2 is one of the essential DNA mismatch repair (MMR) proteins responsible for correcting errors that occur during DNA replication. Loss of PMS2 expression may indicate microsatellite instability (MSI) and can suggest the possibility of Lynch syndrome, a hereditary cancer syndrome linked to colorectal and other cancers.

Microsatellite instability occurs when the DNA mismatch repair system becomes defective, allowing mutations to accumulate in tumor cells. Identifying loss of PMS2 expression helps detect mismatch repair deficiency, which is clinically important for diagnosis, prognosis, and treatment planning. Colorectal cancers with MSI often have distinct biological behavior and may respond better to immunotherapy.

The PMS2 IHC test is usually performed alongside MLH1, MSH2, and MSH6 to provide a complete mismatch repair protein profile and identify hereditary cancer risk accurately.

Benefits of the Test

The PMS2 MSI test provides several clinical benefits:

• Detects loss of PMS2 protein expression
• Identifies microsatellite instability in colorectal tumors
• Helps screen for Lynch syndrome
• Supports accurate tumor classification
• Assists in immunotherapy treatment planning
• Helps assess hereditary cancer risk for family screening

This test is essential for precision oncology and personalized colorectal cancer care.

Why Doctors Recommend This Test

Doctors recommend the PMS2 IHC test when colorectal carcinoma is diagnosed or hereditary mismatch repair deficiency is suspected.

It is commonly advised for:

• Newly diagnosed colorectal cancer patients
• Early-onset colorectal carcinoma cases
• Patients with family history of colorectal or Lynch syndrome-related cancers
• Cases requiring MSI screening
• Advanced molecular tumor profiling

The results help oncologists identify treatment options and guide recommendations for genetic counseling.

Preparation Before Test

No special preparation is required from the patient. The test is performed on previously collected colorectal tissue biopsy or surgical tumor specimens.

Normal Reporting Time

The usual turnaround time for the PMS2 IHC test is 3 to 5 working days, depending on tissue processing and laboratory workflow.

Who Should Take This Test

This test is recommended for:

• Patients diagnosed with colorectal carcinoma
• Individuals with family history of hereditary cancers
• Patients suspected of Lynch syndrome
• Cases requiring mismatch repair deficiency screening
• Oncology patients needing personalized treatment planning

The IHC PMS2 test is an important diagnostic tool in colorectal cancer management. It helps identify mismatch repair defects, evaluate inherited cancer risk, and guide advanced treatment decisions. Early detection supports better patient outcomes and preventive family screening.